JOINN Laboratories' stock soared 14.95% in morning trading following the release of its annual financial results.

The company reported that its net profit attributable to shareholders for 2025 reached RMB 298 million, marking a significant increase of 302.08% compared to the previous year. This substantial growth was primarily driven by gains from changes in the fair value of its biological assets, which amounted to RMB 476 million during the period.

JOINN Laboratories' biological assets consist primarily of non-human primate models used for non-clinical project evaluations, commonly referred to as laboratory monkeys. Despite a 17.87% year-on-year decrease in revenue to RMB 1.658 billion, the strong profit performance and an order backlog of approximately RMB 2.6 billion contributed to positive investor sentiment.